Boehringer brings Striverdi Respimat to market for COPD treatment in US

Boehringer Ingelheim Pharmaceuticals has introduced Striverdi Respimat (olodaterol) inhalation spray 5µg in the US market.

Striverdi Respimat is indicated to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The company noted that Striverdi Respimat is now available by prescription in pharmacies across the country.

“Approximately 15 million Americans have been told by a healthcare provider that they have COPD.”

Boehringer Ingelheim Pharmaceuticals marketing senior vice-president Kathleen Dowd said: “For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases.

“We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option.”

“Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike.”

US Food and Drug Administration (FDA) granted approval for olodaterol in July, which is a long-acting beta agonist (LABA) that can be delivered through the Respimat inhaler.

The approval was based on data from eight Phase III clinical trials, which involved 4,450 patients with COPD.

COPD is a term including chronic bronchitis and emphysema, and the most common symptom of it is shortness of breath. The disease results in harder breathing, as less air is able to flow in and out of the lungs.